Skip to main content
. 2021 May 4;74(2):218–226. doi: 10.1093/cid/ciab394

Figure 2.

Figure 2.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia and clinical severity. A, RNAemic patients had higher mean maximum World Health Organization (WHO) scores (4.80) than non-RNAemic patients (3.24; difference, 1.56 [95% confidence interval [CI], 1.00–2.11]). Severe disease developed in 40.9% of RNAemic patients, compared with 10.2% of non-RNAemic patients (difference, 30.7% [95% CI, 13.9%–47.5%]). Of initially RNAemic patients, 4.5% had mild disease, compared with 35.4% of non-RNAemic patients (difference, 30.8% [95% CI, 19.5%–42.2%]). Equivalent proportions of RNAemic (54.5%) and non-RNAemic (54.4%) patients had disease of moderate severity. B, Among patients with detectable RNAemia at enrollment (n = 44), patients with higher plasma RNA concentrations manifested more severe disease (r = 0.47 [95% CI, .20–.67]). RNA concentrations in RNAemic patients were distributed approximately log normally, so were log scaled for depiction and calculation of correlation. Dashed blue line shows linear correlation between log-scaled plasma RNA concentration and maximum clinical severity.